ReviewCancer gene therapy2015
Manufacturing genetically modified T cells for clinical trials.
Review in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Genetic Code Expanded T Cell for Controllable Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link.Bone marrow transplantation · 2026Article
- In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer.Scientific reports · 2025Article
- The potential of microfluidic cell analysis in CAR T cell therapy manufacturing.Frontiers in bioengineering and biotechnology · 2025Review
- Treg cell therapy manufacturability: current state of the art, challenges and new opportunities.Frontiers in immunology · 2025Review
- Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand.Molecular therapy. Oncology · 2024Article
- TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.Journal of translational medicine · 2024Review
- FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma.Cancer gene therapy · 2024Article
- Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy.Frontiers in molecular medicine · 2024Review
- CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects.Biomedicines · 2023Review
- Potency assays and biomarkers for cell-based advanced therapy medicinal products.Frontiers in immunology · 2023Review
- Understanding CAR T cell therapy and its role in ovarian cancer and peritoneal carcinomatosis from ovarian cancer.Frontiers in oncology · 2023Review
- Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.Frontiers in immunology · 2022Review
- The promise of CD4Haematologica · 2019Review
- GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.Frontiers in immunology · 2019Article
- Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery againstAdvanced therapeutics · 2018Article
- Clinical manufacturing of CAR T cells: foundation of a promising therapy.Molecular therapy oncolytics · 2016Review
- Clinical development of gene therapy: results and lessons from recent successes.Molecular therapy. Methods & clinical development · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Compliance with Food and Drug Administration regulations relating to initiating early phase clinical trials of new cellular therapy products often presents a hurdle to new investigators. One of the biggest obstacles is the requirement to manufacture the therapeutic products under current Good Manufacturing Practices-a system that is usually poorly understood by both basic researchers and clinicians. This article reviews the major points that must be addressed when manufacturing genetically modified T cells for therapeutic use.
Indexed as
Identifiers
25633481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.